The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 10-16

  Rhodes, Lyndsay V ^a   Nitschke, Ashley M ^a   Segar, H Chris ^a   Martin, Elizabeth C ^a   Driver, Jennifer L ^a   Elliott, Steven ^a   Nam, Seung Yoon ^c   Li, Meng ^c   Nephew, Kenneth P ^c   Burow, Matthew E ^a,b   Collins Burow, Bridgette M ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Indiana University School of Medicine   (United States)

Author keywords

Breast cancer; Drug resistance; Histone deacetylase; MCF 7; microRNA; Trichostatin A

Indexed keywords

MICRORNA; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84855283939     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1488     Document Type: Article

References (58)

1. Clarke R, Liu MC, Bouker KB, et al.: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339, 2003. (Pubitemid 37492898)
2. Garcia M, Derocq D, Freiss G and Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89: 11538-11542, 1992.
3. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, et al.: Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27: 542-549, 2009.
4. Ting AH, McGarvey KM and Baylin SB: The cancer epigenome-components and functional correlates. Genes Dev 20: 3215-3231, 2006.
5. Lo PK and Sukumar S: Epigenomics and breast cancer. Pharmacogenomics 9: 1879-1902, 2008.
6. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S and Brodie AM: Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 71: 1893-1903, 2011.
7. Boumber Y and Issa JP: Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226, 228, 2011.
8. Wilkes G: Histone deacetylase inhibitors. Oncology (Williston Park) 21: 39-40, 2007.
9. Zhang S, Cai X, Huang F, Zhong W and Yu Z: Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol 30: 265-268, 2008.
10. Shin S, Lee EM, Cha HJ, et al.: MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 35: 1343-1352, 2009.
11. Bandres E, Agirre X, Bitarte N, et al.: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125: 2737-2743, 2009.
12. Saito Y, Suzuki H, Tsugawa H, et al.: Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28: 2738-2744, 2009.
13. Scott GK, Mattie MD, Berger CE, Benz SC and Benz CC: Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66: 1277-1281, 2006. (Pubitemid 43259904)
14. Ambros V: microRNAs: tiny regulators with great potential. Cell 107: 823-826, 2001.
15. Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369-378, 2009.
16. Weldon CB, Parker AP, Patten D, et al.: Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24: 1473-1480, 2004.
17. Zhou C, Nitschke AM, Xiong W, et al.: Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 10: R105, 2008.
18. Xin F, Li M, Balch C, et al.: Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25: 430-434, 2009.
19. Thomson JM, Parker J, Perou CM and Hammond SM: A custom microarray platform for analysis of microRNA gene expression. Nat Methods 1: 47-53, 2004.
20. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998. (Pubitemid 29003722)
21. Di Leva G, Gasparini P, Piovan C, et al.: MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102: 706-721, 2010.
22. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS and Foroozesh M: Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 52: 5748-5752, 2009.
23. Meacham WD, Antoon JW, Burow ME, Struckhoff AP and Beckman BS: Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 234: 1253-1263, 2009.
24. Foekens JA, Sieuwerts AM, Smid M, et al.: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105: 13021-13026, 2008.
25. Iorio MV, Ferracin M, Liu CG, et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005. (Pubitemid 41161233)
26. Rao X, Di Leva G, Li M, et al.: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082-1097, 2010.
27. Nana-Sinkam SP and Croce CM: MicroRNAs as therapeutic targets in cancer. Transl Res 157: 216-225, 2011.
28. Tavazoie SF, Alarcon C, Oskarsson T, et al.: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
29. Wong CC, Wong CM, Tung EK, et al.: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140: 322-331, 2011.
30. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007. (Pubitemid 47552092)
31. Ma L and Weinberg RA: MicroRNAs in malignant progression. Cell Cycle 7: 570-572, 2008. (Pubitemid 351498993)
32. Atadja PW: HDAC inhibitors and cancer therapy. Prog Drug Res 67: 175-195, 2011.
33. Munster PN, Thurn KT, Thomas S, et al.: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835, 2011.
34. Shankar S and Srivastava RK: Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 615: 261-298, 2008.
35. Lee EM, Shin S, Cha HJ, et al.: Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 24: 45-50, 2009.
36. Saito Y and Jones PA: Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5: 2220-2222, 2006. (Pubitemid 44546557)
37. Saito Y, Liang G, Egger G, et al.: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006. (Pubitemid 43832188)
38. Lujambio A and Esteller M: CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6: 1455-1459, 2007.
39. Yan D, Dong Xda E, Chen X, et al.: MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604, 2009.
40. Nohata N, Sone Y, Hanazawa T, et al.: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2: 29-42, 2011.
41. Yoshino H, Chiyomaru T, Enokida H, et al.: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818, 2011.
42. Xu B, Niu X, Zhang X, et al.: miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350: 207-213, 2011.
43. Zhang H, Cai X, Wang Y, Tang H, Tong D and Ji F: microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 24: 1363-1369, 2010.
44. Sureban SM, May R, Lightfoot S, et al.: DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71: 2328-2338, 2011.
45. Xu J, Liao X and Wong C: Downregulation of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer 126: 1029-1035, 2010.
46. Kong W, He L, Coppola M, et al.: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285: 17869-17879, 2010.
47. Jiang S, Zhang HW, Lu MH, et al.: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70: 3119-3127, 2010.
48. Tili E, Michaille JJ, Cimino A, et al.: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179: 5082-5089, 2007.
49. Meng Z, Fu X, Chen X, et al.: miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 52: 2148-2157, 2010.
50. Kato M, Zhang J, Wang M, et al.: MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 104: 3432-3437, 2007. (Pubitemid 46364176)
51. Scarola M, Schoeftner S, Schneider C and Benetti R: miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res 70: 6925-6933, 2010.
52. Mees ST, Mardin WA, Sielker S, et al.: Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 16: 2339-2350, 2009.
53. Chen H, Sun JG, Cao XW, et al.: Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. Biochem Biophys Res Commun 385: 596-600, 2009.
54. Yamamoto Y, Kosaka N, Tanaka M, et al.: MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14: 529-538, 2009.
55. Chen F, Zhu HH, Zhou LF, Wu SS, Wang J and Chen Z: Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 23: 1457-1462, 2010.
56. Ou Z, Wada T, Gramignoli R, et al.: MicroRNA hsa-miR-613 targets the human LXR(alpha) gene and mediates a feedback loop of LXR(alpha) autoregulation. Mol Endocrinol 25: 584-596, 2011.
57. Shih KK, Qin LX, Tanner EJ, et al.: A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 121: 444-450, 2011.
58. Lv K, Guo Y, Zhang Y, Wang K, Jia Y and Sun S: Allele-specific targeting of hsa-miR-657 to human IGF2R creates a potential mechanism underlying the association of ACAA-insertion/deletion polymorphism with type 2 diabetes. Biochem Biophys Res Commun 374: 101-105, 2008.